Lisocabtagene Maraleucel Approved for Use in Relapsed/Refractory Large B-Cell Lymphoma

被引：0
|
作者：
Schuyler, Devon
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2021年 / 19卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：175 / 175
页数：1
相关论文
共 50 条
  • [1] Lisocabtagene maraleucel for relapsed or refractory large B-cell non-Hodgkin lymphoma
    Mohty, Razan
    Vanegas, Yenny Moreno
    Chavez, Julio C.
    Kharfan-Dabaja, Mohamed A.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (02) : 121 - 126
  • [2] Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed/refractory large B-cell lymphoma
    Patrick, Donald L.
    Powers, Annette
    Jun, Monika Parisi
    Kim, Yeonhee
    Garcia, Jacob
    Dehner, Christine
    Maloney, David G.
    BLOOD ADVANCES, 2021, 5 (08) : 2245 - 2255
  • [3] Tisagenlecleucel and Lisocabtagene Maraleucel: Comparative Efficacy in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Schuster, Stephen J.
    Zhang, Jie
    Yang, Hongbo
    Agarwal, Abhijit
    Tang, Wenxi
    Prieto, Marcela Martinez
    Bollu, Vamsi
    Kuzan, David
    Maziarz, Richard
    Kersten, Marie Jose
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S380 - S381
  • [4] Lisocabtagene maraleucel for treatment of relapsed and refractory primary mediastinal large B-cell lymphoma in an adolescent patient
    Lee, Dasom
    Goyal, Anmol
    Wang, William L.
    Ananth, Snegha
    Lau, Eric
    Binkley, Michael S.
    Bharadwaj, Sushma
    Dahiya, Saurabh
    EJHAEM, 2024, 5 (01): : 153 - 156
  • [5] Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium
    Riedell, Peter A.
    Grady, Connor
    Nastoupil, Loretta J.
    Luna, Alejandro
    Ahmed, Nausheen
    Maziarz, Richard T.
    Hu, Marie
    Brower, Jamie
    Hwang, Wei-Ting
    Schuster, Stephen J.
    Chen, Andy
    Oluwole, Olalekan O.
    Bachanova, Veronika
    McGuirk, Joseph P.
    Perales, Miguel-Angel
    Bishop, Michael R.
    Porter, David L.
    BLOOD, 2023, 142
  • [6] In Vivo Cellular Expansion of Lisocabtagene Maraleucel and Association With Efficacy and Safety in Relapsed/Refractory Large B-Cell Lymphoma
    Ogasawara, Ken
    Lymp, James
    Mack, Timothy
    Dell'Aringa, Justine
    Huang, Chang-pin
    Smith, Jeff
    Peiser, Leanne
    Kostic, Ana
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 112 (01) : 81 - 89
  • [7] Lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis
    Riedell, Peter A.
    Grady, Connor B.
    Nastoupil, Loretta J.
    Luna, Alejandro
    Ahmed, Nausheen
    Maziarz, Richard T.
    Hu, Marie
    Brower, Jamie
    Hwang, Wei-Ting
    Schuster, Stephen J.
    Chen, Andy I.
    Oluwole, Olalekan O.
    Bachanova, Veronika
    Mcgurik, Joseph P.
    Perales, Miguel-Angel
    Bishop, Michael R.
    Porter, David L.
    BLOOD ADVANCES, 2025, 9 (05) : 1232 - 1241
  • [8] LISOCABTAGENE MARALEUCEL FOR RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA: FEASIBILITY, SAFETY AND EFFICACY IN A REAL-WORLD SETTING
    Portuguese, Andrew
    Liang, Emily
    Albittar, Aya
    Hirayama, Alexandre
    Till, Brian
    Cassaday, Ryan
    Lynch, Ryan
    Poh, Christina
    Milano, Filippo
    Chapuis, Aude
    Kiem, Hans-Peter
    Maloney, David G.
    Gauthier, Jordan
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 207 - 208
  • [9] Lisocabtagene Maraleucel for the treatment of B-cell lymphoma
    Iragavarapu, Chaitanya
    Hildebrandt, Gerhard
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (09) : 1151 - 1156
  • [10] Tisagenlecleucel Approved in Relapsed/Refractory Large B-Cell Lymphoma
    Schuyler, Devon
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (06) : 397 - 397
12345